Pyrimidine Compounds for Ubiquitin-Mediated Btk Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Bruton's tyrosine kinase (Btk) inhibition are inadequate, and there is a need for alternative methods that can effectively degrade Btk to modulate B-cell function and treat conditions like chronic lymphocytic leukemia (CLL).
Innovation Solution
Development of compounds that induce proteolytic degradation of Btk via the ubiquitin proteolysis pathway, utilizing ligands to bind Btk and recruit ubiquitin ligases like cereblon (CRBN) for proximity-induced ubiquitination and degradation through the ubiquitin proteasome system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Btk inhibitors are used to block BCR signaling, then B-cell signaling is inhibited, but the Btk protein remains present in the cell and continues to perform protein interactions and scaffolding functions
Solution Approach 1:
The patent extracts and removes the Btk protein from the cell entirely through proteolytic degradation, rather than merely blocking its activity. This is achieved by recruiting ubiquitin ligases to tag Btk for degradation, thereby eliminating not only its kinase activity but also all other functions including protein interactions and scaffolding roles.
Solution Approach 2:
The patent employs the ubiquitin-proteasome system to discard and degrade the Btk protein through controlled proteolysis. The ubiquitin ligase tags Btk with ubiquitin molecules, marking it for degradation by the proteasome, thereby permanently removing the protein from the cell.
2Reliability
If proteolytic degradation of Btk is achieved via ubiquitin proteolysis pathway, then complete Btk removal is accomplished, but the mechanism requires recruitment of ubiquitin ligases and proximity-induced ubiquitination
Solution Approach 1:
The patent uses ubiquitin ligases as intermediary molecules to mediate the degradation of Btk. These ligases act as bridges between the cellular ubiquitin-proteasome system and the Btk protein, facilitating its targeted degradation without requiring direct intervention of the proteasome with the substrate protein.
Solution Approach 2:
The patent replaces simple inhibition mechanisms with a sophisticated biochemical cascade involving ubiquitination. Instead of directly blocking Btk activity, the system uses a multi-step biochemical process where ubiquitin ligases attach ubiquitin molecules to Btk, triggering a conformational change and recruitment of proteasomal degradation machinery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce Btk levels in cells, providing a therapeutic approach for treating CLL by degrading BtkC481S protein, thereby modulating B-cell signaling and potentially alleviating disease symptoms.
Implementation Method 1
compounds that induce the proteolytic degradation of Btk via a ubiquitin proteolysis pathway
Implementation Method 2
induce the proteolytic degradation of Btk via a ubiquitin proteolysis pathway
Data Source
AI summary
The present invention provides for compounds of formula (I)wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.